- Home
- TCRX vs SST Comparison
TCRX vs SST Comparison
Compare TCRX & SST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TCRX | SST |
|---|---|---|
| Founded | 2018 | 2013 |
| Country | United States | United States |
| Employees | N/A | 300 |
| Industry | Biotechnology: Pharmaceutical Preparations | Diversified Commercial Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.6M | 27.4M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | TCRX | SST |
|---|---|---|
| Price | $1.15 | $2.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 1 |
| Target Price | $8.00 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 490.6K | 8.2K |
| Earning Date | 06-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 12.28 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,325,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $69.75 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 266.65 | N/A |
| 52 Week Low | $0.88 | $0.29 |
| 52 Week High | $2.57 | $11.30 |
Technical Indicators
Market Signals| Indicator | TCRX | SST |
|---|---|---|
| Relative Strength Index (RSI) | 56.64 | 28.73 |
| Support Level | $0.90 | $0.34 |
| Resistance Level | $1.23 | $3.57 |
| Average True Range (ATR) | 0.08 | 0.25 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 62.41 | 15.68 |
Price Performance
Historical ComparisonAbout TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
About SST System1 Inc.
System1 Inc develops technology and data science to operate a responsive acquisition marketing platform. It serves customers in the areas of health and wellness, automotive, finance, travel, and entertainment. The company's segment includes Owned and Operated Advertising (O&O); and Partner Network. It generates maximum revenue from the Owned and Operated Advertising (O&O) segment. Geographically, it operates in United States and Other countries.